15th World Bispecific Summit 2024

As of 2023, more than 10 bispecific antibodies have been successfully approved by the FDA, and more than 100 are currently in clinical trials, highlighting biopharma’s continued investment within bispecific therapeutics.

As we look to the future of bispecific drugs and focus on novel formats and exploring new mechanisms to differentiate from the crowd, the 15th World Bispecific Summit continues to be the industry’s one-stop-shop for all your strategic needs within bi, tri or multi-specifics or even bispecific ADCs or BiTEs.

Drug developers across discovery, preclinical and clinical development are joining forces once more to create an improved foothold in this exciting area of drug discovery and bring better and more efficacious bispecific drugs to patients across different disease indications.

Given the reach bispecific drugs can have, the hunt is on for novel targets that can transform the lives of patients, whether it’s new targets and combinations to improve the safety profile for haematological malignancies, overcoming the immunosuppressive microenvironment within solid tumors, or switching the immune system off in autoimmune disease.

Moving towards more personalized medicine, profiling bispecific candidates preclinically to ensure the developability has never been more important. Although time consuming, the benefits in the reduction of the risk and spend is huge in getting candidates into the clinic. Join this meeting to hear novel ideas and concepts, preclinical data, and clinical lessons to enhance the developability of your bispecific drug.



URLs:
Website: https://go.evvnt.com/2403858-0?pid=10018
Tickets: https://go.evvnt.com/2403858-2?pid=10018
Brochure: https://go.evvnt.com/2403858-3?pid=10018
Twitter: https://go.evvnt.com/2403858-4?pid=10018
LinkedIn: https://go.evvnt.com/2403858-5?pid=10018

Prices:
Conference Only - Service Provider: USD 3699.00,
Conference + Seminar Day - Service Provider: USD 5097.00,
Conference Day Only - Academic Pricing: USD 2599.00,
Conference + Seminar Day - Academic Pricing: USD 3597.00,
Conference Only - Drug Developer: USD 2999.00,
Conference + Seminar Day - Drug Developer: USD 4197.00

Speakers: Alexander Martinko, Director - Antibody Engineering and Design, Cartography Biosciences, Inc, Andrew Bayliffe, Chief Scientific Officer, Marengo Therapeutics Inc., Andy Tsun, Co-Founder and Chief Scientific Officer, Biotheus.Inc., Anish Suri, President and Chief Scientific Officer, Cue Biopharma, Annelise Vuidepot, SVP - Chief Technology Officer, Immunocore Ltd, Arne Scheu, Co-Founder and Chief Executive Officer, Valink Therapeutics, Bruce Keyt, Chief Scientific Officer, IGM Biosciences, Cecile Geuijen, Chief Scientific Officer, Merus Therapeutics, David DiLillo, Senior Director, Immuno-Oncology, Regeneron Pharmaceuticals Inc, Flavio Lima Bianchi, Research Analyst, Beacon, Giovanni Abbadessa, Vice President and Head of Oncology Early Development, Sanofi, Jeremy Ross, Scientific Director and Head of Precision Medicine, Hematology Oncology, Abbvie, Kerry Culm, Head of Translational Medicine and Early Development, ModeX Therapeutics, Matthew Chun, Senior Principal Scientist, Amgen Inc., Matthew Faber, Senior Scientist - Protein and Antibody Engineer, Xencor, Mirco Friedrich, Scientist, Broad Institute of MIT and Harvard, Paul Moore, Chief Scientific Officer, Zymeworks, Peng Wu, Professor, The Scripps Research Institute, Peter Aron Sziji, Stanford University, Saso Cemerski, Executive Director, Head of ImmunoOncology Discovery US, AstraZeneca, Shanshan Xu, Vice President - External Innovations, BioNTech, Sherry La Porte, Principal Director, The Strategy and Design Group, Tony Arulanandam, SVP and Head R AND D, Cytovia Therapeutics, Walter Ferlin, Chief Scientific Officer, Light Chain Biosciences, Yue Liu, Chief Executive Officer, Ab Therapeutics, Yuri Teranishi-Ikawa, Principal Scientist, Chugai Pharmaceuticals